(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Bad flu season getting worse; skyrocketing cases set state record - 2Cyclone Narelle turns Australian skies blood red in ‘apocalyptic’ scenes
- 3German police 'cleared path for fascists with batons,' protesters say
- 45 Must-Attempt Fascinating Dishes from Around the World
- 5A company is trying to unlock a key to aging, in a long-overlooked body part
- 2024's Hot Games: Must-Play Titles of the Year
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- IDF destroys Hezbollah rocket launcher used in large rocket salvo towards Haifa, Galilee
- Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Building an Individual Brand: Illustrations from Powerhouses
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Make your choice for the bird that catches your heart!
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
